Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNJ1 | P48048 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 2/20 | 0.37 |
| ▸ | MAOB | P27338 | 2/20 | 0.37 |
| ▸ | CDK2 | P24941 | 4/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 5/20 | 0.35 |
| ▸ | DYRK1B | Q9Y463 | 5/20 | 0.35 |
| ▸ | DYRK2 | Q92630 | 4/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | ERN1 | O75460 | 1/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | TYMS | P04818 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11453548 | 0.81 | KCNJ1 (0.64) | KCNJ1ALDH1A1KMT2AMEN1LMNA | |
| SCHEMBL29386706 | 0.77 | KDM4E (0.41) | KMT2AMEN1LMNATHRBBLM | |
| SCHEMBL6187776 | 0.77 | KDM4E (0.41) | KMT2AMEN1LMNATHRBBLM | |
| SCHEMBL4141000 | 0.76 | PARP1 (0.51) | ALDH1A1KMT2AMEN1LMNAMAOA | |
| SCHEMBL17128311 | 0.76 | PARP10 (0.51) | ALDH1A1KMT2AMAOAMAOBCDK2 | |
| SCHEMBL29112927 | 0.76 | MAOA (0.53) | KCNJ1ALDH1A1MAOAMAOBCDK2 | |
| SCHEMBL31659526 | 0.76 | TYMS (0.40) | ALDH1A1KMT2AMEN1MAOAMAOB | |
| SCHEMBL11741399 | 0.74 | CYP2A6 (0.46) | KCNJ1ALDH1A1KMT2AMEN1LMNA | |
| SCHEMBL15676499 | 0.73 | MAOB (0.38) | KCNJ1ALDH1A1KMT2AMEN1LMNA | |
| SCHEMBL13078852 | 0.73 | ALDH1A1 (0.36) | ALDH1A1KMT2AMEN1LMNAMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240074995-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2024-03-07 | — | — | US | disclosed |
| CN-117257770-A | Transdermal patch for resisting hepatitis B virus and preparation method and application thereof | 泰州市药品检验院(泰州市药品和医疗器械不良反应监测中心) | 2023-12-22 | — | — | CN | disclosed |
| US-11793777-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FIRST WAVE BIO, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-11744812-B2 | Methods of treatment | FIRST WAVE BIO, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-20230201143-A1 | METHODS OF TREATMENT | FIRST WAVE BIO, INC. | 2023-06-29 | — | — | US | disclosed |
| WO-2023118074-A1 | COMPRESSIBLE AND FREE FLOWING CO-PROCESSED MESOPOROUS SILICA | UNIVERZA V LJUBLJANI (SI) | 2023-06-29 | — | — | WO | disclosed |
| US-20230190684-A1 | METHODS OF TREATING COVID-19 WITH A NICLOSAMIDE COMPOUND | FIRST WAVE BIO, INC. | 2023-06-22 | — | — | US | disclosed |
| US-20230102999-A1 | DEUTERATED NICLOSAMIDE | FIRST WAVE BIO, INC. | 2023-03-30 | — | — | US | disclosed |
| US-11564896-B2 | Methods of treatment | FIRST WAVE BIO, INC. (US) | 2023-01-31 | — | — | US | disclosed |
| EP-4045480-A1 | PHARMACEUTICAL FORMULATIONS | First Wave Bio, Inc. (US) | 2022-08-24 | — | — | EP | disclosed |
| US-7927613-B2 | Pharmaceutical co-crystal compositions | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-04-19 | — | — | US | disclosed |
| US-7790905-B2 | Pharmaceutical propylene glycol solvate compositions | MCNEIL-PPC, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| CN-101239982-B | Alkaloids compounds with hepatitis virus resisting activity | TIANJIN INST PHARM RESEARCH | 2010-08-11 | — | — | CN | disclosed |
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2010-01-14 | — | — | US | disclosed |
| CN-101291651-A | External composition for hair growth | AMOREPACIFIC CORP (KR) | 2008-10-22 | — | — | CN | disclosed |
| CN-101239982-A | Alkaloids compounds with hepatitis virus resisting activity | TIANJIN INST PHARM RESEARCH (CN) | 2008-08-13 | — | — | CN | disclosed |
| US-20080161324-A1 | Compositions and methods for treatment of viral diseases | EXCRX (SINGAPORE) PTE. LTD. (F.K.A. COMBINATORX (SINGAPORE) PTE LTD.) (SG) | 2008-07-03 | — | — | US | disclosed |
| WO-2008033466-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PRE. LTD. (SG) | 2008-03-20 | — | — | WO | disclosed |
| JP-2008001602-A | SKIN CARE COMPOSITION | KAO CORP | 2008-01-10 | — | — | JP | disclosed |
| WO-2007046577-A1 | EXTERNAL COMPOSITION FOR HAIR GROWTH | AMOREPACIFIC CORPORATION (KR) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | HTR1A, HTR3B, HTR3A | KCNJ1 1645/4885ALDH1A1 2240/4885KMT2A 1108/4885 |
| US-20240074995-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | KCNJ1 362/4885ALDH1A1 2174/4885KMT2A 3595/4885 |
| US-20230190684-A1 | METHODS OF TREATING COVID-19 WITH A NICLOSAMIDE COMPOUND | ACE2, ACE, MME | KCNJ1 2216/4885ALDH1A1 3497/4885KMT2A 2744/4885 |
| US-11744812-B2 | Methods of treatment | ACE2, ACE, SI | KCNJ1 2484/4885ALDH1A1 3977/4885KMT2A 2952/4885 |
| US-20230201143-A1 | METHODS OF TREATMENT | ACE2, ACE, SI | KCNJ1 1961/4885ALDH1A1 3889/4885KMT2A 2890/4885 |
| US-20080161324-A1 | Compositions and methods for treatment of viral diseases | HAVCR2, EIF2AK2, RNASE1 | KCNJ1 2545/4885ALDH1A1 785/4885KMT2A 2353/4885 |
| US-11564896-B2 | Methods of treatment | ACE2, ACE, SI | KCNJ1 1961/4885ALDH1A1 3889/4885KMT2A 2890/4885 |
| US-20230102999-A1 | DEUTERATED NICLOSAMIDE | FH, IDH2, ECHS1 | KCNJ1 341/4885ALDH1A1 2305/4885KMT2A 2551/4885 |
| US-11793777-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FH, CS, ECHS1 | KCNJ1 374/4885ALDH1A1 2230/4885KMT2A 3704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.